Quantcast

Latest Valeant Pharmaceuticals Stories

2014-06-16 08:29:21

LAVAL, Quebec, June 16, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Restylane® Silk Injectable Gel with 0.3% Lidocaine, a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. "We are pleased to have received marketing clearance from...

2014-06-13 20:21:55

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the...

2014-06-13 12:25:00

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a fact-based presentation to refute recent misleading assertions made by Allergan, Inc. (NYSE: AGN) and others, as well as answer additional investor questions, on June 17, 2014. Conference Call and Webcast Information The Company will host a conference call and a live Internet webcast along with a slide presentation at 8:00 a.m. ET (5:00 a.m....

2014-06-11 08:24:52

Editor Note: For more information about this release, please scroll to bottom. LONDON, June 11, 2014 /PRNewswire/ -- On Tuesday, June 10, 2014, the NASDAQ Composite ended at 4,338.00, up 0.04%, the Dow Jones Industrial Average finished the day 0.02% higher at 16,945.92, and the S&P 500 closed at 1,950.79, down 0.02%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 692.83, up...

2014-06-09 08:29:29

LONDON, June 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Canada Pharmaceuticals and Healthcare Report Q3 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/canada_pharmaceuticals_healthcare_report_q3_2013_1.html Includes 3 FREE quarterly updatesBMI View: The Canadian pharmaceutical and healthcare market will become increasingly attractive to pharmaceutical companies over the next few years as economic growth in the country gradually...

2014-06-09 04:21:23

LAVAL, Quebec, June 9, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia(®) (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails. "We acquired Jublia(®)...

2014-05-30 16:24:44

- Cash of $72.00 per share and 0.83 Shares of Valeant stock LAVAL, Quebec, May 30, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it is making an offer for Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of Allergan shares outstanding. This offer is subject to prompt good faith negotiation of a...

2014-05-28 12:32:31

- Galderma positioned to commercialize Restylane®, Perlane®, Emervel®, Sculptra®, Dysport® in the U.S. and Canada FORT WORTH, Texas, May 28, 2014 /PRNewswire/ -- Galderma Laboratories, L.P. ("Galderma") announced today that Nestle S.A., Switzerland, one of Galderma's shareholders, has entered into an agreement with Valeant Pharmaceuticals International, Inc. and related entities ("Valeant"), through which Galderma will become the distributor of several key products in...

2014-05-28 08:30:03

LAVAL, Quebec, May 28, 2014 /PRNewswire/ -- -- Increases Cash Consideration by $10.00 per share to $58.30, approximately 21 Percent Increase -- Maintains 0.83 of a Valeant share -- Adds Contingent Value Right for DARPin of up to $25.00 per Share in Value -- Valeant Commits to Invest up to $400 Million in DARPin and Retain Current Allergan Employees Responsible for Development -- Represents 40 Percent of DARPin Net Sales after...

2014-05-28 00:21:31

LAVAL, Quebec, May 28, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma. The transaction is subject to customary closing...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related